Loading...
Header Logo
Keywords
Last Name
Institution

William H Meyer

TitleProf
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentDept of Pediatrics
Address1200 N Phillips Ave
Oklahoma City OK 73104-4600
Phone405/271-5311
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    U10CA011233     (MEYER, WILLIAM H)Jan 1, 1978 - Dec 31, 2002
    NIH/NCI
    PEDIATRIC ONCOLOGY GROUP
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Rudzinski ER, Anderson JR, Chi YY, Gastier-Foster JM, Astbury C, Barr FG, Skapek SX, Hawkins DS, Weigel BJ, Pappo A, Meyer WH, Arnold MA, Teot LA, Parham DM. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2017 Dec; 64(12). PMID: 28521080.
      View in: PubMed
    2. Pratap S, Pokala HR, Meyer WH, Gehrs BC, Palacios MF. Diffuse Marrow Involvement in Metastatic Osteosarcoma: An Unusual Presentation. J Oncol Pract. 2017 Jun; 13(6):401-403. PMID: 28437152.
      View in: PubMed
    3. Gupta AA, Chi YY, Anderson JR, Lyden E, Weigel B, Arndt C, Meyer WH, Rosenberg A, Hawkins DS. Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2017 Sep; 64(9). PMID: 28333415.
      View in: PubMed
    4. Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan A, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer. 2017 Jun 15; 123(12):2368-2375. PMID: 28211936.
      View in: PubMed
    5. Meyer WH. Regarding Beau. J Clin Oncol. 2016 Aug 01; 34(22):2669-70. PMID: 27269938.
      View in: PubMed
    6. Weigel BJ, Lyden E, Anderson JR, Meyer WH, Parham DM, Rodeberg DA, Michalski JM, Hawkins DS, Arndt CA. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2016 Jan 10; 34(2):117-22. PMID: 26503200.
      View in: PubMed
    7. Hudson MM, Meyer WH, Pui CH. Progress Born From a Legacy of Collaboration. J Clin Oncol. 2015 Sep 20; 33(27):2935-7. PMID: 26304907.
      View in: PubMed
    8. Oberlin O, Rey A, Brown KL, Bisogno G, Koscielniak E, Stevens MC, Hawkins DS, Meyer WH, La TH, Carli M, Anderson JR. Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups. Pediatr Blood Cancer. 2015 Dec; 62(12):2125-31. PMID: 26257045; PMCID: PMC5002346.
    9. Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan AA, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2014 Nov 01; 32(31):3547-52. PMID: 25267746; PMCID: PMC4209105.
    10. Meyer WH, Grier HE. Comparing oxazaphosphorines for treating Ewing sarcoma: is the answer important two decades later? J Clin Oncol. 2014 Aug 10; 32(23):2401-2. PMID: 24982450.
      View in: PubMed
    11. Green DM, Kun LE, Matthay KK, Meadows AT, Meyer WH, Meyers PA, Spunt SL, Robison LL, Hudson MM. Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. Pediatr Blood Cancer. 2013 Jul; 60(7):1083-94. PMID: 23418018; PMCID: PMC3810072.
    12. Skapek SX, Anderson JR, Hill DA, Henry D, Spunt SL, Meyer W, Kao S, Hoffer FA, Grier HE, Hawkins DS, Raney RB. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study. Pediatr Blood Cancer. 2013 Jul; 60(7):1108-12. PMID: 23281268; PMCID: PMC4646066.
    13. Meyer WH. Playing bad cards properly: challenges to improving cure rates in rhabdomyosarcoma. J Clin Oncol. 2012 Jul 10; 30(20):2431-3. PMID: 22665547.
      View in: PubMed
    14. Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, Maurer HM, Meyer WH, Parham DM, Anderson JR. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2011 Apr 01; 29(10):1312-8. PMID: 21357783; PMCID: PMC3083999.
    15. Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Skapek SX, Hayes-Jordan AA, Donaldson SS, Brown KL, Triche TJ, Meyer WH, Hawkins DS. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2011 Apr 01; 29(10):1304-11. PMID: 21357792; PMCID: PMC3083998.
    16. Walterhouse DO, Meza JL, Breneman JC, Donaldson SS, Hayes-Jordan A, Pappo AS, Arndt C, Raney RB, Meyer WH, Hawkins DS. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 15; 57(1):76-83. PMID: 21298768; PMCID: PMC3459820.
    17. Raney RB, Anderson JR, Brown KL, Huh WW, Maurer HM, Meyer WH, Parham DM, Rodeberg DA, Wolden SL, Donaldson SS. Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Oct; 55(4):612-6. PMID: 20806360; PMCID: PMC3128801.
    18. Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Paidas CN, Parham DM, Anderson JR, Meyer WH, Hawkins DS. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2010 Oct 20; 28(30):4658-63. PMID: 20837952; PMCID: PMC2974343.
    19. McNall-Knapp RY, Williams CN, Reeves EN, Heideman RL, Meyer WH. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors. Pediatr Blood Cancer. 2010 Jul 01; 54(7):909-15. PMID: 20405511.
      View in: PubMed
    20. Khoury JD, Coffin CM, Spunt SL, Anderson JR, Meyer WH, Parham DM. Grading of nonrhabdomyosarcoma soft tissue sarcoma in children and adolescents: a comparison of parameters used for the Fédération Nationale des Centers de Lutte Contre le Cancer and Pediatric Oncology Group Systems. Cancer. 2010 May 01; 116(9):2266-74. PMID: 20166208; PMCID: PMC2987713.
    21. Barr FG, Meyer WH. Role of fusion subtype in Ewing sarcoma. J Clin Oncol. 2010 Apr 20; 28(12):1973-4. PMID: 20308653.
      View in: PubMed
    22. Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. J Clin Oncol. 2010 Mar 01; 28(7):1240-6. PMID: 20124188; PMCID: PMC3040045.
    23. Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol. 2009 Nov 01; 27(31):5182-8. PMID: 19770373; PMCID: PMC2773476.
    24. Rodeberg DA, Stoner JA, Hayes-Jordan A, Kao SC, Wolden SL, Qualman SJ, Meyer WH, Hawkins DS. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol. 2009 Aug 01; 27(22):3705-11. PMID: 19470937; PMCID: PMC3020959.
    25. Qualman S, Lynch J, Bridge J, Parham D, Teot L, Meyer W, Pappo A. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer. 2008 Dec 01; 113(11):3242-7. PMID: 18985676; PMCID: PMC2727712.
    26. Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, Carli M, Anderson JR. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008 May 10; 26(14):2384-9. PMID: 18467730; PMCID: PMC4558625.
    27. Hayes-Jordan A, Stoner JA, Anderson JR, Rodeberg D, Weiner G, Meyer WH, Hawkins DS, Arndt CA, Paidas C. The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the Children's Oncology Group. J Pediatr Surg. 2008 May; 43(5):831-6. PMID: 18485948; PMCID: PMC4646069.
    28. Raney RB, Chintagumpala M, Anderson J, Pappo A, Qualman S, Wharam M, Wiener E, Meyer W. Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997. Pediatr Blood Cancer. 2008 May; 50(5):958-64. PMID: 18240175; PMCID: PMC3357210.
    29. Muir TM, Lehman TP, Meyer WH. Periosteal osteosarcoma in the hand of a pediatric patient: a case report. J Hand Surg Am. 2008 Feb; 33(2):266-8. PMID: 18294553.
      View in: PubMed
    30. Arndt CA, Hawkins DS, Meyer WH, Sencer SF, Neglia JP, Anderson JR. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008 Jan; 50(1):33-6. PMID: 17091486.
      View in: PubMed
    31. Burke M, Anderson JR, Kao SC, Rodeberg D, Qualman SJ, Wolden SL, Meyer WH, Breitfeld PP. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2007 Nov 01; 25(31):4909-13. PMID: 17971587.
      View in: PubMed
    32. Parham DM, Qualman SJ, Teot L, Barr FG, Morotti R, Sorensen PH, Triche TJ, Meyer WH. Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Am J Surg Pathol. 2007 Jun; 31(6):895-901. PMID: 17527077.
      View in: PubMed
    33. Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol. 2007 Feb 01; 25(4):362-9. PMID: 17264331.
      View in: PubMed
    34. Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol. 2006 Aug 20; 24(24):3844-51. PMID: 16921036.
      View in: PubMed
    35. Morotti RA, Nicol KK, Parham DM, Teot LA, Moore J, Hayes J, Meyer W, Qualman SJ. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol. 2006 Aug; 30(8):962-8. PMID: 16861966.
      View in: PubMed
    36. Lager JJ, Lyden ER, Anderson JR, Pappo AS, Meyer WH, Breitfeld PP. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2006 Jul 20; 24(21):3415-22. PMID: 16849756.
      View in: PubMed
    37. Ganti R, Skapek SX, Zhang J, Fuller CE, Wu J, Billups CA, Breitfeld PP, Dalton JD, Meyer WH, Khoury JD. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol. 2006 Sep; 19(9):1213-20. PMID: 16729016.
      View in: PubMed
    38. Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD, Meyer WH. Metastatic osteosarcoma. Cancer. 2006 Jan 15; 106(2):403-12. PMID: 16353204.
      View in: PubMed
    39. Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong KK, Lau CC. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005 Sep 15; 65(18):8142-50. PMID: 16166288.
      View in: PubMed
    40. Chiles MC, Parham DM, Qualman SJ, Teot LA, Bridge JA, Ullrich F, Barr FG, Meyer WH. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group. Pediatr Dev Pathol. 2005 Jan-Feb; 8(1):141. PMID: 15803220.
      View in: PubMed
    41. Chiles MC, Parham DM, Qualman SJ, Teot LA, Bridge JA, Ullrich F, Barr FG, Meyer WH. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group. Pediatr Dev Pathol. 2004 Nov-Dec; 7(6):583-94. PMID: 15630526.
      View in: PubMed
    42. Raney RB, Stoner JA, Walterhouse DO, Andrassy RJ, Donaldson SS, Laurie F, Meyer WH, Qualman SJ, Crist WM. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997. Pediatr Blood Cancer. 2004 Jun; 42(7):618-25. PMID: 15127417.
      View in: PubMed
    43. Wharam MD, Meza J, Anderson J, Breneman JC, Donaldson SS, Fitzgerald TJ, Michalski J, Teot LA, Wiener ES, Meyer WH. Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 2004 May 15; 22(10):1902-8. PMID: 15143083.
      View in: PubMed
    44. Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat Rev. 2004 May; 30(3):269-80. PMID: 15059650.
      View in: PubMed
    45. Sung L, Anderson JR, Arndt C, Raney RB, Meyer WH, Pappo AS. Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. J Pediatr. 2004 May; 144(5):666-8. PMID: 15127010.
      View in: PubMed
    46. Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, Link MP, Daw NC. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer. 2004 Apr 15; 100(8):1724-33. PMID: 15073863.
      View in: PubMed
    47. Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. J Clin Oncol. 2004 Apr 15; 22(8):1398-403. PMID: 15007087.
      View in: PubMed
    48. Qualman SJ, Bowen J, Parham DM, Branton PA, Meyer WH. Protocol for the examination of specimens from patients (children and young adults) with rhabdomyosarcoma. Arch Pathol Lab Med. 2003 Oct; 127(10):1290-7. PMID: 14521467.
      View in: PubMed
    49. Nitschke R, Meyer WH, Huszti HC. When the tumor is not the target, tell the children. J Clin Oncol. 2003 May 01; 21(9 Suppl):40s. PMID: 12743188.
      View in: PubMed
    50. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2003 Jan 01; 21(1):78-84. PMID: 12506174.
      View in: PubMed
    51. Baker KS, Anderson JR, Lobe TE, Wharam MD, Qualman SJ, Raney RB, Ruymann FB, Womer RB, Meyer WH, Link MP, Crist WM. Children from ethnic minorities have benefited equally as other children from contemporary therapy for rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. 2002 Nov 15; 20(22):4428-33. PMID: 12431964.
      View in: PubMed
    52. Rodríguez-Galindo C, Daw NC, Kaste SC, Meyer WH, Dome JS, Pappo AS, Rao BN, Pratt CB. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol. 2002 May; 24(4):250-5. PMID: 11972091.
      View in: PubMed
    53. Athale UH, Stewart C, Kuttesch JF, Moghrabi A, Meyer W, Pratt C, Gajjar A, Heideman RL. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol. 2002 Jan 01; 20(1):88-95. PMID: 11773158.
      View in: PubMed
    54. Meyer WH, Pratt CB, Poquette CA, Rao BN, Parham DM, Marina NM, Pappo AS, Mahmoud HH, Jenkins JJ, Harper J, Neel M, Fletcher BD. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol. 2001 Jan 01; 19(1):171-82. PMID: 11134210.
      View in: PubMed
    Meyer's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _